Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma

Next Previous
Trial Profile

Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pazopanib (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPARZ
  • Sponsors GlaxoSmithKline; GSK; Novartis; Novartis Pharmaceuticals

Most Recent Events

  • 06 Jun 2023 Results of post hoc analysis of COMPARZ study short- and long-term hepatorenal toxicity differences between pazopanib and sunitinib, and to explore the factors predisposing to hepatorenal toxicity assessing presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 06 Jun 2023 Results of post-hoc analysis assessing novel prognostic model for oligometastatic renal cell carcinoma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 16 May 2022 Samples from COMPARZ and IMmotion 150 assessing the relation between FOLH1 expression and angiogenesis, as well as clinical outcomes presented at the 117th Annual Meeting of the American Urological Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top